Neogen (NEOG) vs NovoCure (NVCR)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Neogen (NEOG) has outperformed NovoCure (NVCR) over the past year, gaining 101.2% versus a loss of 0.9%. Over five years, NEOG leads with a -71.5% price change compared with -87.3% for NVCR. Neogen is the larger company by market cap ($2.55 billion vs $1.66 billion), about 1.5 times the size, while NovoCure is growing revenue faster (+8.3% vs -2.7%).
Neogen converts more of its revenue into profit, with a net margin of -0.9% versus -20.8%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | NEOG | NVCR |
|---|---|---|
| Share price | $11.71 | $14.22 |
| Market cap | $2.55B | $1.66B |
| 1-day change | +0.26% | -3.00% |
| YTD return | +67.53% | +9.98% |
| 1-year return | +101.20% | -0.91% |
| 5-year return | -71.47% | -87.33% |
| Forward P/E | 30.82 | — |
| EPS (TTM) | $-0.26 | $-1.30 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $870.40M | $655.35M |
| Revenue growth (YoY) | -2.72% | +8.28% |
| Net income (latest FY) | $-7.90M | $-136.23M |
| Gross margin | 46.93% | 74.54% |
| Operating margin | -2.48% | -23.47% |
| Net margin | -0.91% | -20.79% |
| 52-week high | $14.26 | $21.45 |
| 52-week low | $5.37 | $9.82 |
| Distance from 52-week high | -17.88% | -33.71% |
| Analyst consensus | buy | buy |
| Avg. price target upside | +19.56% | +88.89% |
| Average volume | 3.14M | 1.42M |
| Shares outstanding | 218.11M | 116.45M |
| Employees | 2,636 | 1,605 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: In Vitro & In Vivo Diagnostic Substances | Medical/Dental Instruments |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- NEOG has outperformed NVCR by 102.1 percentage points over the past year.
- Neogen is more profitable, keeping -0.9 cents of every revenue dollar as net income versus -20.8 cents for NovoCure.
- NovoCure grew revenue faster in its latest fiscal year (+8.28% vs -2.72%).
About Neogen
NEOG stock →Neogen Corporation develops, manufactures, and markets various products and services for food and animal safety in the United States and internationally. It operates through Food Safety and Animal Safety segments.
Health Care · Biotechnology: In Vitro & In Vivo Diagnostic Substances · 2,636 employees
About NovoCure
NVCR stock →NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Germany, France, Japan, Greater China, and internationally. Its TTFields devices include Optune Gio, Optune Lua, and Optune Pax.
Health Care · Medical/Dental Instruments · 1,605 employees
NEOG vs NVCR FAQ
Which is bigger, Neogen or NovoCure?
Neogen (NEOG) is larger, with a market capitalization of $2.55B compared with $1.66B for NovoCure (NVCR).
Which stock has performed better over the past year, NEOG or NVCR?
NEOG returned +101.20% over the past 12 months, compared with -0.91% for NVCR (price return, excluding dividends). Past performance does not predict future results.
Are Neogen and NovoCure in the same industry?
Both are in the Health Care sector, but in different industries: Biotechnology: In Vitro & In Vivo Diagnostic Substances for Neogen and Medical/Dental Instruments for NovoCure.